Sorafenib Tosylate

• Catalog No.: S1040
• CAS Number: 475207-59-1
• M. F.: C28H24ClF3N4O6S
• M. W.: 637.0265696
• Storage: -20°C

SYNONYMS

• IUPAC name: 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-methylbenzene-1-sulfonic acid
• IUPAC Traditional name: para-toluene sulfonate sorafenib tosylate
• Synonyms: Bay 43-9006; Nexavar

DATABASE IDS

• CAS Number: 475207-59-1

PROPERTIES

• Target: VEGFR
• Target: PDGFR
• Target: B-Raf
• Salt Data: Tosylate
• Solubility: DMSO
• Storage Condition: -20°C

DETAILS

Description (English)

Research Area

• Description: Cancer

Protocol

• Protocol: Kinase Assay ^[1]
• Biochemical assays: Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl₂, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[^33P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl₂, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.
• Protocol: Cell Assay ^[1]
• Cell Lines: MDA-MB-231, and HAoSMC
• Concentrations: Dissolved in DMSO, final concentrations ~10 μM
• Incubation Time: 72 hours
• Methods: Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP.
• Protocol: Animal Study ^[1]
• Animal Models: Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
• Formulation: Dissolved in Cremophor EL/ethanol (50:50) as 4-fold (4×) stock solution, and diluted to 1× with water
• Doses: ~60 mg/kg
• Administration: Orally once daily

References

• References: [1] Wilhelm SM, et al. Cancer Res, 2004, 64(19), 7099-7109.
• References: [2] Liu L, et al. Cancer Res, 2006, 66(24), 11851-11858.
• References: [3] Ricci MS, et al. Cancer Cell, 2007, 12(1), 66-80.

REFERENCES

• Wilhelm SM, et al. Cancer Res, 2004, 64(19), 7099-7109.
• Liu L, et al. Cancer Res, 2006, 66(24), 11851-11858.
• Ricci MS, et al. Cancer Cell, 2007, 12(1), 66-80.